financetom
Business
financetom
/
Business
/
Matador Resources Q2 Adjusted EPS, Revenue Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Matador Resources Q2 Adjusted EPS, Revenue Increase
Jul 23, 2024 2:08 PM

04:56 PM EDT, 07/23/2024 (MT Newswires) -- Matador Resources ( MTDR ) reported Q2 adjusted earnings late Tuesday of $2.05 per diluted share, up from $1.42 a year earlier.

Analysts polled by Capital IQ expected $1.74.

Revenue for the quarter ended June 30 was $847.1 million, up from $638.1 million a year earlier.

Analysts surveyed by Capital IQ expected $822.5 million.

Price: 62.50, Change: +1.58, Percent Change: +2.59

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Procter & Gamble Lifts Fiscal 2024 Earnings Growth Outlook Following Third-Quarter Profit Beat
Procter & Gamble Lifts Fiscal 2024 Earnings Growth Outlook Following Third-Quarter Profit Beat
Apr 19, 2024
08:23 AM EDT, 04/19/2024 (MT Newswires) -- Procter & Gamble ( PG ) on Friday raised its full-year core earnings growth outlook as the consumer-goods company reported better-than-expected fiscal third-quarter earnings. The maker of Crest toothpaste and Pampers diapers now anticipates adjusted earnings to rise by 10% to 11% for fiscal 2024, above its prior guidance for an 8% to...
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration
Ocugen Completes Dosing in Trial of Gene Therapy for Macular Degeneration
Apr 19, 2024
08:19 AM EDT, 04/19/2024 (MT Newswires) -- Ocugen ( OCGN ) said Friday it has completed dosing in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA), a modifier gene therapy to treat age-related macular degeneration. The company said the trial will evaluate the safety of unilateral subretinal administration of OCU410 in participants with geographic atrophy....
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US
Apr 19, 2024
08:26 AM EDT, 04/19/2024 (MT Newswires) -- Alvotech ( ALVO ) said Friday that it has signed a long-term agreement with an unidentified partner to expand access to Adalimumab-ryvk, a biosimilar to Abbvie's ( ABBV ) drug Humira, in the US. Alvotech's ( ALVO ) chief executive officer, Robert Wessman, said the new partnership agreement supports the biotech company's financial...
Huize Holding, PICC Life Insurance to Launch Critical Illness Insurance Product
Huize Holding, PICC Life Insurance to Launch Critical Illness Insurance Product
Apr 19, 2024
08:25 AM EDT, 04/19/2024 (MT Newswires) -- Huize Holding ( HUIZ ) said Friday it is collaborating with PICC Life Insurance to launch a critical illness insurance product. The company said the i Wu You - Low-Threshold Edition product is expected to offer customized and flexible coverage for 28 severe and three mild illnesses. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved